{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:32:28Z","timestamp":1780486348627,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12020-017-1519-7","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T15:22:31Z","timestamp":1516375351000},"page":"463-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!"],"prefix":"10.1007","volume":"59","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535\u2013559 (2008)","journal-title":"Endocr. Rev."},{"key":"1519_CR2","doi-asserted-by":"crossref","unstructured":"E. Varlamov, M. Fleseriu, Growth hormone deficiency and replacement effect on adult bone mass: a clinical update. Curr. Opin. Endo. Metab. Res. In Press (2018)","DOI":"10.1016\/j.coemr.2017.10.001"},{"key":"1519_CR3","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1210\/jcem.83.9.5072","volume":"83","author":"GI Baroncelli","year":"1998","unstructured":"G.I. Baroncelli, S. Bertelloni, C. Ceccarelli, G. Saggese, Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 83, 3150\u20133154 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1519_CR4","first-page":"2423","volume":"82","author":"AM Boot","year":"1997","unstructured":"A.M. Boot, M.A.M.J. Engels, G.J.M. Boerma, E.P. Krenning, S.M.P.F. de Muinck Keizer-Schrama, Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 82, 2423\u20132428 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1519_CR5","first-page":"669","volume":"78","author":"SJ Holmes","year":"1994","unstructured":"S.J. Holmes, G. Economou, R.W. Whitehouse, J.E. Adams, S.M. Shalet, Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 78, 669\u2013674 (1994)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1519_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1530\/acta.0.1290201","volume":"129","author":"T Rosen","year":"1993","unstructured":"T. Rosen, T. Hansson, H. Granhed, J. Szucs, B.A. Bengtsson, Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. 129, 201\u2013206 (1993)","journal-title":"Acta Endocrinol."},{"key":"1519_CR7","doi-asserted-by":"crossref","unstructured":"N.A. Tritos, A. Klibanski, in Chapter Nine\u2013Effects of Growth Hormone on Bone, ed. by F.F Casanueva. Progress in Molecular Biology and Translational Science, vol 138 (Academic Press publications, London, UK, 2016), pp. 193\u2013211","DOI":"10.1016\/bs.pmbts.2015.10.008"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-016-0859-z","volume":"52","author":"NA Tritos","year":"2016","unstructured":"N.A. Tritos, Skeletal health in adult growth hormone deficiency. Endocrine 52, 1\u20132 (2016)","journal-title":"Endocrine"},{"key":"1519_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2013-3921","volume":"99","author":"M Barake","year":"2014","unstructured":"M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 852\u2013860 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1519_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","volume":"52","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103\u2013110 (2016)","journal-title":"Endocrine"},{"key":"1519_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S2213-8587(15)00098-4","volume":"3","author":"D Mo","year":"2015","unstructured":"D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 3, 331\u2013338 (2015)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1519_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/jbmr.281","volume":"26","author":"C Ohlsson","year":"2011","unstructured":"C. Ohlsson, D. Mellstrom, D. Carlzon, E. Orwoll, O. Ljunggren, M.K. Karlsson, L. Vandenput, Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J. Bone Miner. Res. 26, 865\u2013872 (2011)","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"1519_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12020-017-1440-0","volume":"59","author":"Maya Barake","year":"2017","unstructured":"M. Barake, A. Arabi, N. Nakhoul, G. El-Hajj Fuleihan, S. El Ghandour, A. Klibanski, N.A. Tritos, Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine. (2017) \n                    https:\/\/doi.org\/10.1007\/s12020-017-1440-0","journal-title":"Endocrine"},{"key":"1519_CR14","first-page":"1111","volume":"82","author":"L Holloway","year":"1997","unstructured":"L. Holloway, L. Kohlmeier, K. Kent, R. Marcus, Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 82, 1111\u20131117 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1519_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1359\/jbmr.2003.18.3.393","volume":"18","author":"K Landin-Wilhelmsen","year":"2003","unstructured":"K. Landin-Wilhelmsen, A. Nilsson, I. Bosaeus, B.A. Bengtsson, Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J. Bone Miner. Res. 18, 393\u2013405 (2003)","journal-title":"J. Bone Miner. Res."},{"key":"1519_CR16","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1210\/jc.2015-1757","volume":"100","author":"E Krantz","year":"2015","unstructured":"E. Krantz, P. Trimpou, K. Landin-Wilhelmsen, Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 100, 3251\u20133259 (2015)","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1519-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1519-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1519-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T20:29:15Z","timestamp":1568406555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1519-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1519-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Maria Fleseriu has been a principal investigator with research support to Oregon Health & Science University regarding clinical research studies with NovoNordisk and Pfizer, and she has been previously an occasional scientific consultant for Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}